产品编号 :
Cas No. :
CAS No. |
160162-42-5 |
|---|---|
中文名称 |
3-[1-[(4-氯苯基)甲基]-5-氟-3-甲基吲哚-2-羰基]-2,2-二甲基丙酸 |
英文名称 |
SR 11302 |
别名 |
(E,E,Z,E)-3-Methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid |
标准英文名 |
(2E,4E,6Z,8E)-3-methyl-7-(p-tolyl)-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid |
MDL No. |
MFCD09038562 |
分子式 |
C26H32O2 |
分子量 |
376.54 |
精确分子量 |
376.24 |
SMILES |
O=C(O)/C=C(C)/C=C/C=C(C1=CC=C(C)C=C1)/C=C/C2=C(C)CCCC2(C)C |
标准SMILES |
CC1CCCC(C)(C)C=1/C=C/C(=C/C=C/C(/C)=C/C(O)=O)/C1C=CC(C)=CC=1 |
用途 |
SR11302 is used as an inhibitor of the activator protein-1 (AP-1) transcription factor; it specifically suppresses AP-1 activity without activating retinoic acid response element (RARE)-mediated transcription. It is applied in research on AP-1-related pathways, including studies on aldosterone regulation under hypoxia, Helicobacter pylori-induced gastric adenocarcinoma cell proliferation, and β-catenin/c-myc expression. In vivo, SR11302 is used to reduce vascular lesion number and size in Vldlr⁻/⁻ mouse models of retinal angiogenesis, demonstrating dose-dependent efficacy without observable toxicity. |
InChIKey |
RQANARBNMTXCDM-DKOHIBGUSA-N |
|
|
评论 |
|---|